Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study  by John, T. et al.
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a  b  s  t  r  a  c  t
This  serological  follow  up  study  assessed  the  kinetics  of  antibody  response  in  children  who  previously
participated  in  a single  centre,  open-label,  randomised  controlled  trial  of low-dose  compared  to  standard-
dose diphtheria  booster  preschool  vaccinations  in  the United  Kingdom  (UK).  Children  had previously  been
randomised  to receive  one  of  three  combination  vaccines:  either  a combined  adsorbed  tetanus,  low-dose
diphtheria,  5-component  acellular  pertussis  and  inactivated  polio  vaccine  (IPV)  (Tdap–IPV,  Repevax®;
Sanoﬁ  Pasteur  MSD);  a combined  adsorbed  tetanus,  low-dose  diphtheria  and  5-component  acellular
pertussis  vaccine  (Tdap,  Covaxis®; Sanoﬁ  Pasteur  MSD)  given  concomitantly  with  oral  polio  vaccine
(OPV);  or  a  combined  adsorbed  standard-dose  diphtheria,  tetanus,  2-component  acellular  pertussis  and
IPV (DTap–IPV,  Tetravac®; Sanoﬁ  Pasteur  MSD).  Blood  samples  for  the  follow-up  study  were  taken  at  1,
3  and  5 years  after  participation  in  the  original  trial  (median,  5.07  years  of  age  at year 1),  and  antibody
persistence  to  each  vaccine  antigen  measured  against  deﬁned  serological  thresholds  of  protection.
All participants  had evidence  of  immunity  to  diphtheria  with  antitoxin  concentrations  greater  than
0.01  IU/mL  ﬁve  years  after  booster  vaccination  and  75%,  67%  and 79%  of  children  who  received Tdap–IPV,
Tdap  +  OPV  and  DTap–IPV,  respectively,  had protective  antitoxin  levels  greater  than  0.1 IU/mL.  Long  last-
ing protective  immune  responses  to  tetanus  and  polio  antigens  were  also  observed  in  all  groups,  though
polio  responses  were  lower  in  the  sera  of  those  who  received  OPV.
Low-dose  diphtheria  vaccines  provided  comparable  protection  to the standard-dose  vaccine  and  are
suitable  for use  for pre-school  booster  vaccination.
ublis©  2015  The  Authors.  P∗ Corresponding author.A.J. Pollard Tel.: +44 1865 234226.
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1. Introduction
Children receive multiple doses of diphtheria vaccine in the
United Kingdom (UK) immunisation schedule both as diph-
theria toxoid antigen (5 doses by 15 years of age) and as a
mutant diphtheria toxoid protein, CRM197, a component of sev-
eral protein–polysaccharide conjugate vaccines (up to 4 doses).
The importance of maintaining diphtheria immunity through
immunisation is emphasised by outbreaks of diphtheria where
immunisation programmes break down, as seen in India [1] and
Nigeria [2]. However, diphtheria toxoid causes local reactions and
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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or this reason, to improve tolerability without compromising
rotection, several vaccines have been developed containing a low-
ose of the antigen in an attempt to reduce reactogenicity.
In 2001, the UK infant immunisation programme provided pro-
ection against Haemophilus inﬂuenzae type b (Hib), diphtheria
D), tetanus (T), pertussis with 3 doses of a whole cell pertussis
wP) combination vaccine administered in the ﬁrst 4 months of
ife together with oral poliomyelitis vaccine (OPV). At that time,
hildren received their ﬁrst booster dose of diphtheria toxoid in
ombination with tetanus toxoid (with OPV and measles, mumps
nd rubella (MMR)  vaccines; DT + OPV + MMR)  before school entry
nd at least 3 years after completion of the infant 2-, 3- and 4-month
rimary course [3].
Concerns over local reactions (mainly erythema and indura-
ion) following multiple booster doses of diphtheria antigen during
hildhood have been raised. Although at the time of the primary
tudy low-dose diphtheria (d) vaccine was recommended in the
K for children over the age of 10 years receiving the vaccine as
art of the adolescent booster, recommendations for a low-dose
iphtheria vaccine did not exist for younger children [3].
To ensure reduced reactogenicity and enhance population
mmunity against pertussis, acellular pertussis (aP/ap) vaccine was
dded to the pre-school booster in the UK in 2001; aP vaccines are
referred over wP vaccines, particularly for boosters, because they
re associated with fewer local and systemic adverse events [4–6].
n 2004 inactivated polio vaccine (IPV) was introduced to replace
he live OPV [7]. Unlike OPV, IPV does not carry a risk of vaccine-
ssociated paralysis [8]. In addition, IPV can be incorporated into
ombination vaccines, simplifying immunisation schedules [9].
We commenced a study in 2001 comparing the immunogenicity
nd reactogenicity of one low-dose and one standard-dose diph-
heria vaccine combined with tetanus, acellular pertussis and IPV
Tdap–IPV and DTap–IPV) and of one low-dose diphtheria vaccine
ombined with tetanus and acellular pertussis and given concomi-
antly with OPV (Tdap + OPV) as a pre-school booster in UK children
9]. The study comprised Visit 1 (baseline blood draw and vaccina-
ion) and Visit 2 (post-vaccination blood draw 28 to 42 days later).
hree hundred children, 100 children per vaccine group, were vac-
inated at a mean age of 3.9 years. Full study details and results have
een reported previously and showed robust immue  responses fol-
owing immunisation with all three vaccines at 1 month [10].
The vaccines studied (Tdap–IPV, Tdap + OPV and DTap–IPV)
ere all sufﬁciently immunogenic for use as a pre-school booster in
he UK, despite Tdap–IPV and Tdap containing a lower diphtheria
ose, and could be administered concomitantly with MMR  vaccine.
ll three combinations were well tolerated [10].
able 1
ntigen concentrations of Tdap–IPV, Tdap + OPV and DTap–IPV.
Tdap–IPV 
Puriﬁed tetanus toxoid ≥20 IU 
Puriﬁed diphtheria toxoid ≥2 IU 
Puriﬁed pertussis toxoid (PT) 2.5 g 
Puriﬁed  ﬁlamentous haemagglutinin (FHA) 5 g 
Puriﬁed  ﬁmbriae types 2 + 3 (FIM) 5 g 
Puriﬁed pertactin (PRN) 3 g 
Inactivated poliomyelitis virus type 1 40D antigen units 
Inactivated poliomyelitis virus type 2 8D antigen units 
Inactivated poliomyelitis virus type 3 32D antigen units 
Live  attenuated type 1 poliovirus – 
Live  attenuated type 2 poliovirus – 
Live  attenuated type 3 poliovirus – 
bbreviations: Tdap–IPV: combined adsorbed tetanus, low-dose diphtheria, 5-componen
dap  + OPV: combined adsorbed tetanus, low-dose diphtheria and 5-component acellula
olio  vaccine; DTap–IPV: combined adsorbed standard-dose diphtheria, tetanus, 2-comp
SD).(2015) 4579–4585
The objective of this extended follow-up study was  to evaluate
the persistence of immunity 1, 3 and 5 years after administration
of this pre-school booster vaccine.
2. Methods
2.1. Participants and vaccines
Study visits were performed at approximately 1, 3 and 5 years
after children had received one of 3 different pre-school booster
vaccines at an age of 3.5–5 years in a single centre (Oxford Vac-
cine Group, Churchill Hospital, Oxford, UK) open-label, randomised,
controlled, Phase III study.
In the original clinical trial children aged 3.5–5 years were ran-
domly assigned to one of three study groups: a combined adsorbed
tetanus, low-dose diphtheria, 5-component acellular pertussis and
IPV (Tdap–IPV, Repevax[®]; Sanoﬁ Pasteur MSD);  a combined
adsorbed tetanus, low-dose diphtheria and 5-component acel-
lular pertussis vaccine (Tdap, Covaxis[®]; Sanoﬁ Pasteur MSD)
given concomitantly with OPV; or a combined adsorbed diphthe-
ria, tetanus, 2-component acellular pertussis and IPV (DTap–IPV,
Tetravac®; Sanoﬁ Pasteur MSD). In all groups, MMR  vaccine was
optionally given concomitantly.
The two  low-dose diphtheria vaccines (Tdap–IPV and Tdap)
contained pertactin (PRN) and ﬁmbriae (FIM) types 2 + 3, as
well as reduced quantities of pertussis toxoid (PT) and ﬁlamen-
tous haemagglutinin (FHA). The standard-dose diphtheria vaccine
(DTaP–IPV) contained only PT and FHA (Table 1).
All children vaccinated in the initial study and who had not been
excluded or withdrawn were eligible for inclusion in the follow-up
study.
The objective of the follow-up study was  to evaluate the persis-
tence of antibodies to the vaccine antigens (diphtheria, tetanus,
PT, FHA, PRN, FIM, and poliomyelitis types 1, 2, and 3) 1, 3,
and 5 years after receipt of the study vaccines. The 1 year visit
occurred between January and November 2003, year 3 between
December 2004 and November 2005 and year 5 between January
and November 2007, 60 to 63 months after the date of the original
study vaccine administration.
At each visit a 5.0 mL  sample of venous blood was  obtained;
participation at each timepoint was  optional and non-participation
at one timepoint was  not an exclusion criterion for future partic-
ipation. No vaccines were administered as part of the follow-up
study, although anyone identiﬁed as having low antibody levels to
a particular antigen were advised to receive a further dose of the
appropriate vaccine.
Tdap + OPV DTap–IPV
Tdap OPV
≥20 IU – ≥40 IU
≥2 IU – ≥30 IU
2.5 g – 25 g
5 g – 25 g
5 g – –
3 g –
- – 40D antigen units
– – 8D antigen units
– – 32D antigen units
– ≥106 TCID50 –
– ≥105 TCID50 –
– ≥105.5 TCID50 –
t acellular pertussis and inactivated polio vaccine (Repevax®; Sanoﬁ Pasteur MSD);
r pertussis vaccine (Covaxis®; Sanoﬁ Pasteur MSD) given concomitantly with oral
onent acellular pertussis and inactivated polio vaccine (Tetravac®; Sanoﬁ Pasteur
ne 33 
t
R
w
c
p
2
f
s
a
t
p
r
i
t
t
b
o
b
(
y
c
f
p
n
p
s
r
F
a
(
pT. John et al. / Vacci
The study was conducted in accordance with the principles of
he Declaration of Helsinki and had the approval of the Oxfordshire
esearch Ethics Committee (C01.183). Signed, informed consent
as obtained from a parent at each study visit prior to any pro-
edure being performed. Verbal agreement was  obtained from the
articipant.
.2. Immunogenicity and safety assessments
Immune responses were measured by seroneutralisation (SN)
or diphtheria and poliovirus antigens and by enzyme immunoas-
ays (EIA) for tetanus and pertussis antigens (PT, FHA, PRN
nd FIM). Seroprotection was deﬁned as a diphtheria antibody
itre (SN) ≥ 0.1 IU/mL; tetanus antibody titre (EIA) ≥ 0.1 IU/mL; and
oliovirus types 1, 2 and 3 antibody titre (SN) ≥ 8 (1/dilution),
espectively. In addition to seroprotection rates, basic clinical
mmunity to diphtheria and tetanus were deﬁned as an antibody
itre ≥0.01 IU/mL. In the absence of an agreed correlate of protec-
ion, no thresholds of response for pertussis antigens were deﬁned
ut GMCs were calculated.
Samples obtained at year 1 were analysed in Aventis Pasteur lab-
ratories in Canada. From year 3 onwards all assays were performed
y the Global Clinical Immunology platform of Sanoﬁ Pasteur Inc.
Swiftwater, PA, USA) In order to compare the results obtained at
ear 1 with those obtained at year 3 an year 5, laboratory con-
ordance studies were performed. As a consequence, conversion
actors were applied for the results of diphtheria, tetanus and
oliomyelitis types 1 and 2 at year 1 but this was deemed not
ecessary for the other valences, i.e. for type 3 poliomyelitis and
ertussis.
No safety assessments were carried out during the follow-up
tudy as no vaccines were given. Only serious adverse events
elated to the blood sampling process were recorded.
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2.3. Statistics
The immunogenicity endpoints for 5-year post-booster persis-
tence were basic clinical immunity and seroprotection rates for
diphtheria, tetanus and type 1, 2 and 3 poliovirus antigens.
Immunogenicity analyses were performed for the intention-
to-treat (ITT) population. The ITT population at the 5-year visit
comprised all children included in the ITT population in the primary
study who  had a blood sample at year 5. In addition, the antibody
data at year 1 and year 3, are also presented for the sub-population
of participants included in the ITT population at year 5.
Geometric mean antibody concentrations/titres (GMCs/GMTs),
and their 2-sided 95% conﬁdence intervals (CIs) were calculated
for immunogenicity criteria. In addition, the proportions of par-
ticipants with antibody concentrations/titres against pre-deﬁned
accepted thresholds were calculated.
The sample size was  calculated for the primary study. Only
descriptive statistical analyses were performed in the follow-
up study, which was  not powered for antibody persistence. No
hypotheses relating to expected response rates were formulated.
3. Results
3.1. Study population
Randomisation and follow-up of children is shown in Fig. 1. In
total, of the 300 children who  were enrolled into the initial study,
219 children participated at year 1 (73.0%), 161 (53.7%) at year 3
and 146 (48.7%) at year 5. 140 children were included in the ITT
population at year 5. A subset of these children also had results
available at year 1 (n = 117) and year 3 (n = 113) and are therefore
included in this analysis.
At year 1 children were aged between 4.51 and 6.18 years (mean
age 5.07), year 3 aged between 6.50 and 8.09 (mean age 7.08 years)
and at year 5, children were aged between 8.56 and 10.13 years
NDOMISED
n=300
n=100
 +OPV  & MMR
n=100
DTa P-I PV & MMR
th Post vaccine
pleted: 100
1 month  Post Vacc ine
Complete d: 99
• Blood sample traumac 
for child: n=1
sent given:  75
mplete d: 75
Consent given:  75
Completed: 74
• Blood sample traumac 
for child: n=1 
sent given:  62
mplete d: 60
 sample 
cessful: n=2 
Consent given:  51
Complete d: 48
• Blood sample not 
performed/refused: n=3 
sent given:  56
mplete d: 54
 sample refused: 
Consent given:  41
Complete d: 38
• Blood sample r efused: 
n=3 
ombined adsorbed tetanus, low-dose diphtheria, 5-component acellular pertussis
sorbed tetanus, low-dose diphtheria and 5-component acellular pertussis vaccine
: combined adsorbed standard-dose diphtheria, tetanus, 2-component acellular
mumps  and rubella vaccine (optionally given concomitantly).
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Table 2
Demographic characteristics (intention-to-treat population at each Visit).
Year Tdap–IPV Tdap + OPV DTap–IPV
Age (years) Mean (SD)
min–max
1 5.11 (0.38) 5.05 (0.32) 5.05 (0.35)
4.54–6.18 4.57–5.90 4.51–6.09
3 7.1  (0.35) 7.06 (0.33) 7.09 (0.30)
6.69–8.01 6.61–8.09 6.5–7.91
5 9.07 (0.37) 9.05 (0.27) 9.06 (0.35)
8.59–9.96 8.56–9.71 8.65–10.13
Sex n(%) male 1 31 (44.93%) 30 (40.00%) 39 (54.17%)
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s.3  20 (42.55%) 21 (35.00%) 24 (51.06%)
5  21 (43.75%) 18 (33.33%) 21 (55.26%)
mean age: 9.06 years). At all 3 timepoints age of participant was
imilar among the three groups. Throughout the study slightly more
irls participated than boys (Table 2).
.2. Antibody persistence
Antibody levels were lower at the ﬁrst visit in this study (year 1)
han they had been at 1 month after vaccination in the initial study
10]. Five years after receipt of vaccine all participants had diph-
heria antitoxin concentrations ≥0.01 IU/mL. Furthermore, 75.00%,
6.67% and 78.95% of children who received Tdap–IPV, Tdap + OPV
nd DTap–IPV, respectively, maintained protective antibody levels
or diphtheria concentrations ≥0.1 IU/mL (Table 3).
All participants had tetanus antitoxin titres ≥0.01 IU/mL; 100%,
6.30% and 89.47% of children who received Tdap–IPV, Tdap + OPV
nd DTap–IPV, respectively, had titres ≥0.1 IU/mL at the 5 year
ollow up visit (Table 3). Tetanus GMCs were slightly lower in the
Tap–IPV group than in the other 2 groups at all timepoints but CIs
verlapped except at year 5 (Table 3).
Five years after receipt of the pre-school vaccine(s), seroprotec-
ion rates for type 1 poliomyelitis were 97.87%, 96.23% and 100%
or Tdap–IPV, Tdap + OPV and DTap–IPV, respectively. All partic-
pants had a titre of ≥1:8 for type 2 poliomyelitis in the three
accine groups. Seroprotection rates for type 3 poliomyelitis were
5.74% (45/47 children) and 97.37% (37/38 children) for Tdap–IPV
nd DTap–IPV, respectively. In contrast, 9 children out of 53 did
ot reach the threshold in the Tdap + OPV group, corresponding to
 seroprotection rate of 83.02% (Table 4). Polio GMTs were lower at
ll timepoints in the OPV group than in the IPV groups (Table 4).
Persisting antibody responses against pertussis antigens were
bserved in all groups for PT and FHA and also for PRN and FIM
n the Tdap–IPV and Tdap + OPV groups as these antigens are not
ontained in the DTap–IPV vaccine (Table 5).
During the initial study 2 participants that received the
dap + OPV vaccines were identiﬁed as not having achieved protec-
ive antibody levels either for diphtheria or for polio. The relevant
ooster vaccine was administered and the individual with low polio
itres, who participated at all 3 follow-up visits, was not included in
he polio analysis and the individual with low diphtheria antibody
evels, who participated at the 1 year timepoint, was not included
n the diphtheria and tetanus analysis. At year 3, three years after
eceipt of the DTap–IPV vaccine, one participant had not main-
ained protective antibody levels for diphtheria and was  advised
o receive a booster dose of vaccine and did not participate at the
ve year timepoint.
There were no serious adverse events associated with the blood
ampling procedure carried out at any of the 3 follow up visits.. Discussion
This study reports on the persistence of antibody up to 5
ears following receipt of one of 3 pre-school booster vaccinations Ta
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Table 4
Antibody responses to poliovirus types 1, 2, and 3 at 1, 3 and 5 years after a booster dose of Tdap–IPV, Tdap + OPV or DTap–IPV (intention-to-treat population at year 5).
Tdap–IPV  Tdap  +  OPV  DTap–IPV
Time  post
booster
1  Year  3  Year  5  Year  1  Year  3  Year  5 Year  1  Year  3  Year  5  Year
N 37  36 47  46 47  53 32  29  38
Polio 1 %  ≥1:8  [95%  CI]  100* [90.59–100]  100  [90.36–100]  97.87  [88.89–99.62]  100* [92.29;100]  100* [92.44–100]  96.23  [87.25–98.96]  100* [89.28–100]  100  [88.30–100]  100  [90.82–100]
GMT [95%  CI]  338.74* [267.04–429.69]  284.59  [195.41–414.45]  101.85  [73.86–140.43]  112.42* [89.95–140.52]  112.09* [81.16–154.80]  64.01  [46.87–87.42]  322.89* [234.85–443.94]  357.74* [243.40–525.80]  124.55  [90.01–172.34]
Polio 2 %  ≥1:8  [95%  CI]  100* [90.59–100]  100  [90.36–100]  100  [92.44–100]  100* [92.29–100]  100* [92.44–100]  100  [93.24–100]  100* [89.28–100]  100  [88.30–100]  100  [90.82–100]
GMT [95%  CI]  471.59* [356.21–624.35]  341.72  [252.84–461.84]  202.19  [164.58–248.39]  167.23* [135.32–206.67]  153.91* [115.16–205.69]  106.58  [84.37–134.64]  531.83* [363.84–777.38]  393.60  [257.25–602.21]  211.37  [144.17–309.90]
Polio 3 %  ≥1:8  [95%  CI]  100  [90.59–100]  97.22 [85.83–99.51]  95.74  [85.75–98.83]  100  [92.29–100]  97.87  [88.89–99.62]  83.02  [70.77–90.80]  100  [89.28–100]  96.55  [82.82–99.39]  97.37  [86.51–99.53]
GMT [95%  CI]  1043.37  [711.24–1530.58]  414.27  [248.34–691.09]  147.26 [101.81–213.00]  98.33 [71.42–135.38]  38.19  [28.85–50.56]  16.75  [13.07–21.47]  1104.65  [770.60–1583.50]  389.05  [239.04–633.19]  145.43  [101.79–207.76]
Abbreviations: CI: conﬁdence interval; GMT: geometric mean titres. Tdap–IPV: combined adsorbed tetanus, low-dose diphtheria, 5-component acellular pertussis and inactivated polio vaccine (Repevax®; Sanoﬁ Pasteur MSD);
Tdap  + OPV: combined adsorbed tetanus, low-dose diphtheria and 5-component acellular pertussis vaccine (Covaxis®; Sanoﬁ Pasteur MSD) given concomitantly with oral polio vaccine; DTap–IPV: combined adsorbed standard-
dose  diphtheria, tetanus, 2-component acellular pertussis and inactivated polio vaccine (Tetravac®; Sanoﬁ Pasteur MSD)
%  percentage of subjects; * converted data; CI, conﬁdence interval; GMT, geometric mean titres.
Table 5
Geometric mean concentrations of pertussis antibodies at 1, 3 and 5 years after a booster dose of Tdap–IPV, Tdap + OPV or DTap–IPV (intention-to-treat population at year 5).
Tdap–IPV  Tdap  +  OPV  DTap–IPV
Time  post  booster  1  Year  3  Year  5  Year  1  Year  3 Year  5 Year  1  Year  3  Year  5 Year
PT N  37  36  38  46  47  41  32  28  33
GMC (EU/mL)  [95%  CI]  26.51  [16.89–41.61]  5.83  [4.08–8.34]  7.98 [4.88–13.05]  32.96  [22.28–48.77]  7.88  [4.99–12.44]  8.06  [4.76–13.66]  12.86  [8.40–19.67]  6.24  [3.98–9.79]  4.98  [3.23–7.67]
FHA N 37  36  46  47  45  54  33  29  38
GMC (EU/mL)  [95%  CI]  22.76  [16.01–32.35]  16.99  [11.39–25.34]  26.86  [20.64–34.95]  29.69  [21.96–40.14]  32.13  [21.46–48.10]  38.77  [28.53–52.71]  36.85  [26.11–52.01]  38.99  [24.19–62.86]  41.29  [29.71–57.38]
PRN N 37  36  47  47  48  54  33  29  38
GMC (EU/mL)  [95%  CI]  40.16  [24.72–65.24]  18.51  [12.60–27.18]  18.13  [12.95–25.39]  54.33  [33.36–88.48]  30.89  [21.21–44.99]  26.82  [18.14–39.67]  2.98  [2.16–4.11]  3.64  [2.74–4.82]  3.84  [2.90–5.08]
FIM N 36  36  47  47  48  52  33  29  34
GMC (EU/mL)  [95%  CI]  126.00  [65.45–242.56]  66.56  [46.05–96.21]  63.62  [42.93–94.28]  154.86 [96.78–247.79]  90.43  [64.42–126.95]  74.32  [52.39–105.42]  14.70  [10.11–21.39]  11.56  [6.81–19.62]  10.21  [6.39–16.33]
PT, pertussis toxoid; FHA, ﬁlamentous haemagglutinin; PRN, pertactin; FIM, ﬁmbriae types 2 + 3; CI, conﬁdence interval; GMC, geometric mean concentrations. Abbreviations: PT: pertussis toxoid; FHA: ﬁlamentous haemagglutinin;
PRN:  pertactin; FIM: ﬁmbriae types 2 + 3; CI: conﬁdence interval; GMC: geometric mean concentrations. Tdap–IPV: combined adsorbed tetanus, low-dose diphtheria, 5-component acellular pertussis and inactivated polio vaccine
(Repevax®; Sanoﬁ Pasteur MSD); Tdap + OPV: combined adsorbed tetanus, low-dose diphtheria and 5-component acellular pertussis vaccine (Covaxis®; Sanoﬁ Pasteur MSD) given concomitantly with oral polio vaccine; DTap–IPV:
combined  adsorbed standard-dose diphtheria, tetanus, 2-component acellular pertussis and inactivated polio vaccine (Tetravac®; Sanoﬁ Pasteur MSD).
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dministered in a clinical trial of children aged 3.5 to 5 years in
001. Following a rapid decline in the ﬁrst year for all antibod-
es [10], the data from this study demonstrate that a low-dose
iphtheria toxoid-containing vaccine (Tdap–IPV and Tdap) pro-
ides long-lasting immune responses for all antigens with levels of
mmunity being broadly similar to those achieved with standard-
ose diphtheria toxoid vaccines (DTap–IPV). All 3 vaccines studied
n the primary study are suitable for use as a pre-school booster to
rovide a fourth dose of the contained antigens.
Overall there were slightly more females than males in the study
ut this reﬂected the original study population (55% versus 45%).
00 children participated in the initial study of which 219, 161
nd 146 participated at 1, 3 and 5 years, respectively. The reten-
ion rate is not dissimilar to other studies conducted in cohorts of
hildren in Oxford (unpublished observations). By the 5-year time
oint it was known that several families had moved away from
he area but reasons for non-participation amongst the remain-
ng children are largely unknown. A separate qualitative study,
onducted with the cohort of children approached for the initial
accine study, identiﬁed anxiety of blood sampling and temper-
ment of child as reasons for non-participation [11]. While these
iews were expressed in relation to a study involving a new vac-
ine it is likely the issues remain relevant when making a decision
hether or not to participate in a study involving just a blood sam-
le.
The proportion of children maintaining persistence of antibod-
es above accepted seroprotection levels for diphtheria, tetanus,
nd poliomyelitis were similar to those reported in a previous
tudy, in which seroprotective antibody levels against diphthe-
ia, tetanus, types 1–3 poliomyelitis and Hib were maintained
–5 years after primary vaccination and a ﬁrst booster with the
Tap–IPV–Hib vaccine Pentavac® [12]. Furthermore, while a Ger-
an  study demonstrated that diphtheria antitoxin titres wane over
he ﬁrst year following vaccination irrespective of the initial titre,
t has been suggested that the protection afforded by low-dose
iphtheria containing combinations may  still persist through to
dolescence [13]. This follow-up study supports lasting protection
gainst diphtheria for up to 5 years following receipt of a pre-school
ooster vaccine. It is noteworthy that, although the point estimates
or the low dose diphtheria vaccine-induced anti-toxin concentra-
ions are slightly lower at each timepoint than the standard dose
accine levels, none of these concentrations were signiﬁcantly dif-
erent as conﬁdence intervals overlapped substantially.
While there are widely accepted reference levels for full pro-
ection against diphtheria (antitoxin concentrations ≥0.1 IU/mL)
14] and tetanus (antitoxin concentrations ≥0.1 IU/mL) [15] there
emain no clear serological correlates of protection for pertussis
rom large scale ﬁeld studies, which makes it difﬁcult to interpret
he immunogenicity of the pertussis components of the vaccines in
he original study [10]. Antibodies to PT, FHA, PRN and FIM were
herefore measured by EIA using in-house reference standards.
espite some waning, the data from the study show persistence
f antibody responses against PT and FHA pertussis antigens in all
roups and also for PRN and FIM in the 2 groups that received a
-component acellular pertussis vaccine.
As the study was not powered to show any intergroup statis-
ical differences a comparative analysis of results across the three
reatment groups in this follow-up antibody persistence study was
ot attempted. However, serum polio responses were more robust
n the groups receiving IPV than the OPV group at almost all time
oints (non-overlapping CIs). Since mucosal responses were not
easured, differences in protection induced by these different vac-ine strategies cannot be determined. We  also noted that the there
s a rise in some of the pertussis antibody concentrations between
he 3 and 5 year timepoints, which we propose may  reﬂect natural
oosting.
[(2015) 4579–4585
In conclusion, a pre-school booster vaccine containing a low-
dose diphtheria toxoid (Tdap–IPV or Tdap + OPV) demonstrates
comparable persistent immunity for diphtheria, tetanus and per-
tussis antigens to a standard-dose diphtheria toxoid vaccine
(DTap–IPV) 5 years after administration to children aged as young
as 3.5 years living in the UK.
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